Skip to main content

Table 3 Characteristics of patients with clinical cardiotoxicity

From: Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation

Patient Clinical manifestation of cardiotoxicity Day after HSCT Baseline NT-proBNP/hs-cTnT NT-proBNP/hs-cTnT Conditioning regimen CD ANT (mg/m2)
1 Chest pain, dyspnea 3 237/normal 9589/0,032 TBI + CY 390
2 Chest pain, dyspnea 1 320/normal 12 156/0,076 FLAMSA 125
3 Fluid retention, pericarditis 15 327/normal 3761/0,016 TBI + CY 150
4 Fluid retention 10 412/0,025 4817/
0,047
BUCY2 470
5 Cardiogenic shock 176 63,88/0,018 31 444/0,05 TBI + CY 150
  1. ANT anthracyclines, CY cyclophosphamide, hs-cTnT high sensitive cardiac troponin T, NT-proBNP N-terminal pro-B-type natriuretic peptide, TBI total body irradiation, CD cumulative dose, FLAMSA fludarabine + cytosine arabinosid + TBI + CY + amsacrine was replaced by idarubicin, BU busulphan